Zymeworks hits 52-week high as $250 million milestone lifts profit

By Marcus Bennett

Zymeworks (Nasdaq: ZYME) generated $512.92 million in third-quarter revenue, more than twice the $227.40 million analyst consensus and 828.7% above the prior-year quarter. EPS (earnings per share) reached $2.28, beating the cited $2.27 consensus by $0.01 but missing Zacks' $2.40 estimate. A $250 million milestone payment from Jazz Pharmaceuticals helped produce the profit, making recurring performance harder to assess.

Shares reached a new 52-week high of $31.97 on Tuesday after the earnings report. They last traded at $30.91 on volume of 286,303 shares, versus the previous close of $30.81; a separate market summary described the shares as trading up 1.3%.

What does the earnings quality show?

The quarter produced EPS of $2.28 versus a loss of $0.26 per share in the prior-year quarter. Zymeworks reported negative return on equity (profit relative to shareholder equity) of 72.30% and a negative net margin (profit relative to revenue) of 405.31%.

Zymeworks raised its 2026 earnings guidance, strengthening the near-term outlook after the report. The $250 million milestone may prove nonrecurring, so practitioners still need to separate that payment from the underlying earnings run rate.

MarketBeat data showed a consensus “Moderate Buy” rating and an average price target (an analyst's expected share price) of $41.75. With a $2.20 billion market capitalization, Zymeworks traded at a price-to-earnings ratio of -15.40 and a beta (share-price volatility measure) of 1.32.

The 50-day moving average stood at $27.46, above the 200-day average of $25.38. The $31.97 intraday high sat above both measures, while the recurring-versus-one-off question remained central to the earnings interpretation.

How have analysts changed their assessments?

Brokerage price targets moved higher across several firms during the coverage cycle. The actions combined reiterated ratings with one new initiation.

• B. Riley Financial, Aug. 10: Reiterated a “Buy” rating and raised its target to $44 from $40.
• JPMorgan Chase, Sept. 3: Lifted its target to $33 from $31 and retained an “Overweight” rating, indicating expected outperformance.
• HC Wainwright, Tuesday: Maintained a “Buy” rating and raised its target to $56 from $55.
• TD Cowen, Sept. 29: Initiated coverage with a “Buy” rating and a $34 target.
• Jefferies, Oct. 23: Reiterated a “Buy” rating and set a $52 target.

Twelve analysts rated Zymeworks Buy, one assigned Hold and one assigned Sell. The $33-to-$56 target range shows continued dispersion among valuation assessments, despite the positive rating majority.

What did the insider sale change?

Executive vice president Adam Schayowitz sold 13,832 shares on Oct. 9 at an average price of $25.85, totaling $357,557.20. The trade reduced his position by 37.35%, leaving him with 23,205 shares valued at $599,849.25.

A filing with the Securities and Exchange Commission reported that the sale covered tax withholding obligations related to vesting equity awards. Insiders own 37.73% of the company, making the remaining stake material to the ownership structure.

What do institutional filings show?

Large investors reported position increases during the first and second quarters. Nykredit established a separate new position, while the other firms disclosed additions to existing holdings.

• Janney Montgomery Scott LLC: Increased its stake 3.8% in the first quarter, adding 420 shares to reach 11,487 shares worth $288,000.
• Tema ETFs LLC: Added 684 shares in the second quarter, raising its stake 0.7% to 105,615 shares worth $2,761,000.
• Tidal Investments LLC: Added 684 shares in the second quarter, also increasing its stake 0.7% to 105,615 shares worth $2,761,000.
• Allspring Global Investments Holdings LLC: Raised its position 10.4% in the first quarter by 800 shares, reaching 8,507 shares worth $221,000.
• Nykredit A S: Established a new second-quarter position valued at $25,000.

Hedge funds and other institutional investors own 92.89% of Zymeworks. That concentration makes quarterly position filings and future ownership changes a relevant monitoring point for professional investors.

What does the company sell?

Zymeworks is a Vancouver, Canada-based biotechnology company developing engineered medicines for cancer and other serious diseases. Its antibody-engineering technologies aim to create therapies that engage multiple biological targets or modify immune responses.

The lead program is zanidatamab, a HER2-targeted bispecific antibody, meaning an antibody designed to engage two targets. Jazz Pharmaceuticals markets zanidatamab in the United States as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Jazz's role as marketing partner links the milestone to reported quarterly profit. The forward test is whether Zymeworks can sustain earnings once the $250 million payment leaves the comparison base.